A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients

Brain

Volumn 135, Issue 1, 2012, Pages 72-87

  Fledrich, Robert ^a   Schlotter Weigel, Beate ^b   Schnizer, Tuuli J ^a   Wichert, Sven P ^a   Stassart, Ruth M ^a   Meyer Zu Hörste, Gerd ^c   Klink, Axel ^a   Weiss, Bernhard G ^a   Haag, Uwe ^d   Walter, Maggie C ^b   Rautenstrauss, Bernd ^e   Paulus, Walter ^f   Rossner, Moritz J ^a   Sereda, Michael W ^a,f  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d HaaPACS GmbH   (Germany)

^e Medizinisch Genetisches Zentrum (MGZ)   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

biomarker; Charcot Marie Tooth disease; CMT rat model; disease progression; lipid metabolism; translation

Indexed keywords

CARBOXYPEPTIDASE C; GLUTATHIONE TRANSFERASE T1; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTOME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENETIC TRANSCRIPTION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LIPID METABOLISM; MALE; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RNA EXTRACTION; SCIATIC NERVE; SKIN BIOPSY;

EID: 84856712027     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr322     Document Type: Article

References (58)

1. Bannon AW, Malmberg AB. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci 2007; Chapter 8: Unit 8 9.
2. Berciano J, Garcia A, Calleja J, Combarros O. Clinico- electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with charcot-marie-tooth disease 1A duplication. Neuromuscul Disord 2000; 10: 419-24. (Pubitemid 30433812)
3. Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8: 537-44.
4. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: L. Erlbaum Associates; 1988.
5. Dacci P, Dina G, Cerri F, Previtali SC, Lopez ID, Lauria G, et al. Foot pad skin biopsy in mouse models of hereditary neuropathy. Glia 58: 2005-16.
6. de Visser M, Verhamme C. Ascorbic acid for treatment in CMT1A: what s next? Lancet Neurol10: 291-3.
7. Evans JD. Straightforward statistics for the behavioral sciences. Pacific Grove, CA: Brooks/Cole Pub. Co.; 1996.
8. Garbay B, Heape AM, Sargueil F, Cassagne C. Myelin synthesis in the peripheral nervous system. Prog Neurobiol 2000; 61: 267-304. (Pubitemid 30155722)
9. Garcia CA, Malamut RE, England JD, Parry GS, Liu P, Lupski JR. Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology 1995; 45: 2090-3.
10. Genin E, Feingold J, Clerget-Darpoux F. Identifying modifier genes of monogenic disease: strategies and difficulties. Hum Genet 2008; 124: 357-68.
11. Giambonini-Brugnoli G, Buchstaller J, Sommer L, Suter U, Mantei N. Distinct disease mechanisms in peripheral neuropathies due to altered peripheral myelin protein 22 gene dosage or a Pmp22 point mutation. Neurobiol Dis 2005; 18: 656-68. (Pubitemid 40332723)
12. Kaku DA, Parry GJ, Malamut R, Lupski JR, Garcia CA. Nerve conduction studies in Charcot-Marie-Tooth polyneuropathy associated with a segmental duplication of chromosome 17. Neurology 1993; 43: 1806-8. (Pubitemid 23307959)
13. Kanitakis J. Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol 2002; 12: 390-9; quiz 400-1.
14. Karlsson U, Schultz RL. Fixation of the central nervous system from electron microscopy by aldehyde perfusion. I. preservation with aldehyde perfusates versus direct perfusion with osmium tetroxide with special reference to membranes and the extracellular space. J Ultrastruct Res 1965; 12: 160-86.
15. Katona I, Wu X, Feely SM, Sottile S, Siskind CE, Miller LJ, et al. PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain 2009; 132: 1734-40.
16. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000; 123 (Pt 7): 1516-27. (Pubitemid 30420950)
17. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008; 17: 303-40.
18. Lauria G, Cazzato D, Porretta-Serapiglia C, Casanova-Molla J, Taiana M, Penza P, et al. Morphometry of dermal nerve fibers in human skin. Neurology 2011; 77: 242-9.
19. Li J, Bai Y, Ghandour K, Qin P, Grandis M, Trostinskaia A, et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 2005; 128: 1168-77. (Pubitemid 40675470)
20. Luft JH. Improvements in epoxy resin embedding methods. J Biophys Biochem Cytol 1961; 9: 409-14.
21. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991; 66: 219-32. (Pubitemid 121001361)
22. Maeda T, Kiguchi N, Kobayashi Y, Ozaki M, Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008; 108: 341-7.
23. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997; 62: 310-8. (Pubitemid 27199100)
24. Matsunami N, Smith B, Ballard L, Lensch MW, Robertson M, Albertsen H, et al. Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat Genet 1992; 1: 176-9.
25. Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore-and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979; 1: 233-6. (Pubitemid 11204691)
26. Meyer zu Hörste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007; 61: 61-72. (Pubitemid 46214245)
27. Micallef J, Attarian S, Dubourg O, Gonnaud PM, Hogrel JY, Stojkovic T, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8: 1103-10.
28. Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA 2003; 100: 605-10. (Pubitemid 36126099)
29. Pareyson D, Marchesi C, Salsano E. Hereditary predominantly motor neuropathies. Curr Opin Neurol 2009; 22: 451-9.
30. Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011; 10: 320-8.
31. Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007; 320: 1002-12. (Pubitemid 46294061)
32. Parman Y. Hereditary neuropathies. Curr Opin Neurol 2007; 20: 542-7. (Pubitemid 47462283)
33. Patel PI, Roa BB, Welcher AA, Schoener-Scott R, Trask BJ, Pentao L, et al. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nat Genet 1992; 1: 159-65.
34. Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation 123: 1116-24.
35. Raeymaekers P, Timmerman V, Nelis E, De Jonghe P, Hoogendijk JE, Baas F, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1991; 1: 93-7.
36. Reilly MM, de Jonghe P, Pareyson D. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord 2006; 16: 396-402.
37. Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 2010; 839-46.
38. Rossner MJ, Hirrlinger J, Wichert SP, Boehm C, Newrzella D, Hiemisch H, et al. Global transcriptome analysis of genetically identified neurons in the adult cortex. J Neurosci 2006; 26: 9956-66. (Pubitemid 44477157)
39. Saher G, Quintes S, Mobius W, Wehr MC, Kramer-Albers EM, Brugger B, et al. Cholesterol regulates the endoplasmic reticulum exit of the major membrane protein P0 required for peripheral myelin compaction. J Neurosci 2009; 29: 6094-104.
40. Saporta MA, Katona I, Lewis RA, Masse S, Shy ME, Li J. Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain 2009; 132: 3263-73.
41. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43: 205-18. (Pubitemid 20385185)
42. Sereda M, Griffiths I, Puhlhofer A, Stewart H, Rossner MJ, Zimmerman F, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 1996; 16: 1049-60. (Pubitemid 26171699)
43. Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9: 1533-7.
44. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005a; 64: 1209-14.
45. Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008; 70: 378-83. (Pubitemid 351653401)
46. Shy ME, Lupski JR, Chance PF, Klein CJ, Dyck PJ. Hereditary motor and sensory neuropathies: an overview of clinical, geneti, electrophysiolo-gic, and pathologic features. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy. Vol. 2. Philadelphia: Elsevier Saunders; 2005b. p. 1623-58.
47. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth s disease. Clin Genet 1974; 6: 98-118.
48. Steiner I, Gotkine M, Steiner-Birmanns B, Biran I, Silverstein S, Abeliovich D, et al. Increased severity over generations of Charcot-Marie-Tooth disease type 1A. J Neurol 2008; 255: 813-9.
49. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50. (Pubitemid 41528093)
50. Thomas PK, Marques W Jr, Davis MB, Sweeney MG, King RH, Bradley JL, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997; 120 (Pt 3): 465-78. (Pubitemid 27153639)
51. Timmerman V, Nelis E, Van Hul W, Nieuwenhuijsen BW, Chen KL, Wang S, et al. The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nat Genet 1992; 1: 171-5.
52. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008; 77: 289-312.
53. Valentijn LJ, Bolhuis PA, Zorn I, Hoogendijk JE, van den Bosch N, Hensels GW, et al. The peripheral myelin gene PMP-22/GAS-3 is duplicated in Charcot-Marie-Tooth disease type 1A. Nat Genet 1992; 1: 166-70.
54. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
55. Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, van Schaik IN. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009; 7: 70.
56. Vigo T, Nobbio L, Hummelen PV, Abbruzzese M, Mancardi G, Verpoorten N, et al. Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis. Mol Cell Neurosci 2005; 28: 703-14. (Pubitemid 40387885)
57. Yiu EM, Burns J, Ryan MM, Ouvrier RA. Neurophysiologic abnormalities in children with Charcot-Marie-Tooth disease type 1A. J Peripher Nerv Syst 2008; 13: 236-41.
58. Young P, De Jonghe P, Stogbauer F, Butterfass-Bahloul T. Treatment for Charcot-Marie-Tooth disease. Cochrane Database Syst Rev 2008; CD006052.